ASCO Publishes Two Independent Research Programs from Malecare

Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO). At the last ASCO GU Conference Malecare presented a poster and had published an [...]

Who will respond to Zytiga (Abiraterone) and Xtandi (Enzalutamide)?

We have many new drugs that have been recently approved to treat advanced prostate cancer. Two of these drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). These drugs offer new hope to men with advanced prostate cancer after the cancer has become resistant to hormone therapies (called "castration-resistant prostate cancer"). These drugs are a real breakthrough, [...]

Become A Patron of Prostate Cancer Research – Go to

Start A Cure Update -What Went Wrong: Eliminating Mistakes in Diagnosis and Treatment of Prostate Cancer Malecare’s Start A Cure web site has begun to function in earnest. We at Malecare have become concerned about the increasing loss of funding for prostate cancer research, so we have started a “crowd funding” project to let individuals [...]

Announcing A New Research Platform – Start A Cure

The news is in, and it is bad. It is as bad as many of us feared. The National Institute of Health (NIH) has announced that their across-the-board budget sequester cuts are going to equal 1.71 billion dollars. The NIH is responsible for the majority of cancer research performed in the United States. For the [...]

That Dirty Word Sequester & Its Terrible Effect on Cancer Research & Treatment

That dirty word, sequester is making it mark, especially medical and cancer research. Hospitals and researchers are feeling the pain directly and hard. The National Institutes of Health (NIH), for example, is cutting an estimated $1.6 billion from its budget through the end of the fiscal year. They have sent a letter to all of [...]

Responding to the Fear of Cancer – Being Honest

Everyone who reads this blog regularly knows that I am a passionate advocate for increased funding in the fight against cancer, especially prostate cancer. However, sometimes it is a good idea to push back from the table and evaluate the true nature of a situation. The Harris poll has published a recent survey which concluded [...]

Taxane-Based Chemotherapy Drugs May Be Underestimated, Especially Against Advanced Prostate Cancer

According to researchers at Weill Cornell Medical College in the Sept. 15 issue of the journal Cancer Research, taxne-based chemotherapy drugs are not well understood as they may be more powerful than many have believed. Generally, it is believed that taxane chemotherapy (paclitaxel, docetaxel and cabazitaxel) just stop a cancer cell from dividing -- but [...]

Some Important Themes From The 2012 AACR Meeting

Last week I had the privilege of attending the Annual 2012 American Association of Cancer Researchers (AACR) in Chicago through the generosity of the Scientist-Survivor Program. The meeting involved five days of educational sessions, symposia and posters. In the course of the next week or so, I will be discussing some of the prostate cancer [...]

By |2017-10-19T10:51:14-04:00April 10th, 2012|AACR, Advanced Prostate Cancer, Research, Uncategorized|0 Comments

Protect the Department of Defense CDMRP Prostate Cancer Research Program (DoD PCRP)

YOUR DEADLINE: WEDNESDAY, JUNE 22, 2011 On Wednesday and Thursday, the House will meet at 10:00 a.m. for Morning Hour debate and 12:00 p.m. for legislative business. H.R. 2219, the Department of Defense Appropriations Act, 2012 (Rep. Young (FL) - Appropriations), has been placed on the House calendar for then. As part of H.R. 2219 [...]

Status Update on the Budget and It’s Implications for Cancer Research

As of now, Congress and the Administration are at an impasse on FY 11 spending.  If no deal is reached by Friday, government operations will shut down.  This would impact cancer research and prevention programs in the following ways: *   Patient enrollment in clinical trials would be discontinued; *   No new grants would be awarded; [...]